Sun Enters Japan Through Divested Novartis Portfolio
This article was originally published in Scrip
Executive Summary
Sun Pharmaceutical Industries Ltd. is entering the Japanese pharma market by acquiring a bundle of 14 established prescription brands from Novartis AG's local subsidiary, in an anticipated move that echoes a similar transaction between Takeda Pharmaceutical Co. Ltd. and Teva Pharmaceutical Industries Ltd. last year.
You may also be interested in...
Nichi-Iko Aims For ‘Commanding Presence’ In Japan Generics Via Eisai Alliance
Eisai has become the latest R&D-based pharma company in Japan to offload its non-innovative products as it seeks to maximize their sales and focus more on novelty and, by implication, the rewards this can bring under Japan’s evolving reimbursement pricing system.
Nichi-Iko Aims For ‘Commanding Presence’ In Japan Generics Via Eisai Alliance
Eisai has become the latest R&D-based pharma company in Japan to offload its non-innovative products as it seeks to maximize their sales and focus more on novelty and, by implication, the rewards this can bring under Japan’s evolving reimbursement pricing system.
Astellas Offloads Japan Product Basket To Private Equity Group
Astellas has joined the growing ranks of research-based pharma firms offloading their older products in Japan, amid rising pricing and generic pressures and an increasing desire to focus on innovation.